Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis

Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis

Systemic sclerosis (SSc) is an intractable autoimmune disease characterized by vasculopathy and organ fibrosis. Autologous hematopoietic stem cell transplantation (AHSCT) should be considered for the treatment of selected patients with rapid progressive SSc at high risk of organ failure. It, however...

Full description

Bibliographic Details
Main Authors: Paul Gressenberger, Philipp Jud, Gabor Kovacs, Sonja Kreuzer, Hans-Peter Brezinsek, Katharina Guetl, Viktoria Muster, Ewald Kolesnik, Albrecht Schmidt, Balazs Odler, Gabriel Adelsmayr, Peter Neumeister, Luka Brcic, Sabine Zenz, Kurt Weber, Thomas Gary, Marianne Brodmann, Winfried B. Graninger, Florentine C. Moazedi-Fürst
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Journal of Personalized Medicine
Subjects:
systemic sclerosis
rituximab
autologous hematopoietic stem cell transplantation
Online Access:https://www.mdpi.com/2075-4426/11/7/600

Internet

https://www.mdpi.com/2075-4426/11/7/600

Similar Items